Florida is currently home to 3768 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Harmony TPV Post-Approval Study
Recruiting
The purpose of this study is to characterize the functionality of transcatheter implantation of the Medtronic Harmony Transcatheter Pulmonary Valve (TPV) achieved by real-world implanters.
Gender:
ALL
Ages:
All
Trial Updated:
03/19/2025
Locations: St. Joseph Children's Hospital, Tampa, Florida
Conditions: Congenital Heart Disease, Tetrology of Fallot, RVOT Anomaly, Pulmonary Regurgitation
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in Pt. W/ Metastatic PAC
Recruiting
This is a Phase I/Ib trial, single-center, non-randomized, open-label study of Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) and G+TTF maintenance therapy in patients with metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Adenocarcinoma
Bikini vs Longitudinal Incision in Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)
Recruiting
The study team is conducting this study to see if there is a difference between the wound healing and participant satisfaction rates between two incision types used during a THA done via the DAA technique.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: University of Miami, Miami, Florida
Conditions: THA
Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT
Recruiting
The primary objective of this study is to compare total narcotic intake standardized via milligram morphine equivalents between duloxetine and placebo cohorts after a total hip arthroplasty.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: University of Miami, Miami, Florida
Conditions: THA
A Single-center Study of Setmelanotide in Patients With Prader-Willi Syndrome
Recruiting
This is a Phase 2, single-center, open-label study designed to assess the safety and efficacy of setmelanotide in patients with obesity due to Prader-Willi Syndrome (PWS) who are 6 to 65 years of age. Up to 20 patients are planned to be enrolled. Patients will take a daily subcutaneous dose of open-label setmelanotide for up to 26 weeks.
Gender:
ALL
Ages:
Between 6 years and 65 years
Trial Updated:
03/18/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Prader-Willi Syndrome, Obesity, Hyperphagia
A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer
Recruiting
The researchers are doing this study to find out if a personalized approach to chemoradiation therapy (which may include a lower dose of radiation) is as effective as the standard chemoradiation therapy in people with HPV-positive throat cancer. Other purposes of this study include looking at the following: * Whether a lower dose of radiation in combination with standard chemotherapy causes fewer side effects than the standard dose of radiation therapy in combination with standard chemotherapy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Baptist Alliance MCI (Data Collection Only), Miami, Florida
Conditions: HPV-Related Squamous Cell Carcinoma
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Recruiting
The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are: Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)? What medical problems are observed in participants who take GATE-251? Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants w... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/18/2025
Locations: Clinical Neuroscience Solutions, Inc., Jacksonville, Florida
Conditions: Major Depressive Disorder
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Recruiting
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovar... Read More
Gender:
FEMALE
Ages:
39 years and below
Trial Updated:
03/18/2025
Locations: Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
VTP-1000 in Adults with Celiac Disease
Recruiting
GLU001 is a first-in-human clinical trial to assess the safety and tolerability of VTP-1000 for adults with celiac disease. This trial will assess VTP-1000 at various dose levels compared to placebo in a single ascending dose (SAD) and multiple ascending dose (MAD) format. Participants will be followed for a short period of time to assess the impact of VTP-1000 on their immune system (Adverse events, reactions in the blood, and physical exam differences). Participants enrolled in the MAD portion... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/18/2025
Locations: Jacksonville Center for Clinical Research, Jacksonville, Florida
Conditions: Celiac Disease
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome
Recruiting
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Dermatology Associates of Tallahassee, Tallahassee, Florida
Conditions: Gorlin Syndrome
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Recruiting
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: BRCR Global, Tamarac, Florida
Conditions: Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Recruiting
The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Non-small Cell Lung Cancer